RESET® Endoscopic Therapy
Type 2 Diabetes and Obesity
Phase 2Active
Key Facts
About Morphic Medical
Morphic Medical is a private, clinical-stage medical device company pioneering a novel approach to treating type 2 diabetes and obesity. Its core technology, the RESET® therapy, is an endoscopically implanted device that aims to address the root physiological causes of these diseases, offering a potential alternative for patients underserved by drugs but not candidates for surgery. The company is currently advancing RESET® through a U.S. clinical trial (STEP-1) and is positioned to address a massive global market with significant unmet need. Morphic represents a convergence of gastroenterology and metabolic disease treatment with a minimally invasive device platform.
View full company profileTherapeutic Areas
Other Type 2 Diabetes and Obesity Drugs
| Drug | Company | Phase |
|---|---|---|
| GLP-1 Agonist (Semaglutide) Trials | Clinical Investigation Specialists | Phase 3 |